```html

Jabir’s Disease (Adult‑Onset Still’s Disease)

Overview

Jabir’s disease is another name for Adult‑Onset Still’s Disease (AOSD), a rare systemic inflammatory disorder that typically begins in adulthood. It is characterized by high‑grade fevers, a distinctive salmon‑pink rash, and severe joint pain. The disease shares features with the childhood condition known as systemic juvenile idiopathic arthritis (sJIA), but it appears after the age of 16.

Who it affects

• Age: Usually 20–40 years, but cases have been reported from adolescence to the seventh decade.
• Sex: Slight female predominance (≈ 55 % women).

Prevalence

• Estimated incidence: 0.16–0.4 cases per 100,000 persons per year worldwide.<sup>[1][2]</sup>
• Prevalence is higher in Northern Europe and Japan, but the disease occurs on all continents.

Symptoms

Symptoms can appear abruptly and often fluctuate (“spiking fevers”). The classic triad is fever, rash, and arthritis, but many patients experience additional systemic features.

Core symptoms

• Fever – Daily spikes ≥ 39 °C (102 °F), often highest in the late afternoon or early evening; may be > 40 °C.
• Rash – Salmon‑pink maculopapular eruption, usually non‑pruritic, that appears with the fever and fades as the temperature drops.
• Arthritis/arthralgia – Joint pain, swelling, and stiffness, frequently affecting wrists, knees, ankles, and elbows; can become chronic.

Systemic manifestations

• Muscle pain (myalgia) and weakness
• Sore throat (pharyngitis) that may precede fever
• Lymphadenopathy (enlarged lymph nodes)
• Hepatomegaly or splenomegaly (enlarged liver or spleen)
• Serositis – inflammation of the lining of the heart (pericarditis), lungs (pleuritis), or abdomen (peritonitis)
• Shortness of breath or chest pain (often due to pleuritis or pericardial effusion)
• Weight loss and fatigue
• Elevated ferritin levels (> 3,000 ng/mL in many cases) – a key laboratory clue

Rare/late‑onset features

• Macrophage activation syndrome (MAS) – a life‑threatening hyperinflammatory state
• Interstitial lung disease
• Neurological involvement (encephalopathy, seizures)
• Renal dysfunction (rare)

Causes and Risk Factors

The exact cause of AOSD remains unknown, but research points to an abnormal immune response triggered by genetic and environmental factors.

Potential triggers

• Infections – viral (e.g., Epstein‑Barr, parvovirus B19) or bacterial agents have been reported preceding disease onset.
• Vaccinations – isolated case reports describe symptom onset after certain vaccines, but causality is unproven.

Genetic predisposition

• Associations with HLA‑B17, HLA‑B35, and HLA‑DR2 alleles have been identified, suggesting a role for specific immune‑related genes.
• Family clustering is rare, indicating a modest hereditary component.

Risk factors

• Age 16–40 years (peak incidence)
• Female sex (slight predominance)
• History of a recent infection or intense immune stimulus

Diagnosis

Because no single test confirms AOSD, diagnosis relies on a combination of clinical criteria, exclusion of mimicking diseases, and supportive laboratory findings.

Classification criteria

• Yamaguchi criteria (most widely used) – require ≥ 5 features, with at least 2 being major (fever, rash, arthritis, leukocytosis). Minor criteria include sore throat, lymphadenopathy, liver dysfunction, and negative rheumatoid factor (RF) or antinuclear antibody (ANA).<sup>[3]</sup>
• Fautrel criteria – incorporate serum ferritin > 3,000 ng/mL and glycosylated ferritin < 20 % as major items.<sup>[4]</sup>

Laboratory tests

• Complete blood count – marked neutrophilic leukocytosis (> 10 × 10⁹/L)
• Elevated ESR and CRP (inflammatory markers)
• Serum ferritin – often > 5,000 ng/mL; glycosylated ferritin fraction low
• Liver function tests – mild transaminase elevation
• Negative autoantibodies (RF, ANA, anti‑CCP) help exclude rheumatoid arthritis and lupus

Imaging & other studies

• Chest X‑ray or CT – evaluate pleuritis, pericardial effusion, or interstitial lung disease.
• Ultrasound/MRI of joints – assess synovitis, erosions; helps differentiate from rheumatoid arthritis.
• Bone marrow aspirate – rarely needed, but can rule out malignancy when ferritin is extremely high.

Exclusion of mimics

Infection (sepsis, endocarditis), malignancy (especially lymphoma), and other autoimmune diseases must be ruled out before confirming AOSD.

Treatment Options

Treatment aims to control systemic inflammation, relieve joint pain, and prevent organ damage. Therapy is individualized according to disease severity and organ involvement.

First‑line pharmacologic therapy

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – naproxen, ibuprofen, or indomethacin can reduce fever and arthralgia. Not sufficient for severe disease.
• Corticosteroids – Prednisone 0.5–1 mg/kg/day is the backbone of initial treatment; rapid symptom control in most patients. Tapering is guided by clinical response and ferritin trends.

Targeted & disease‑modifying agents

• IL‑1 inhibitors – Anakinra (daily subcutaneous) and canakinumab (monthly) are highly effective, especially in steroid‑refractory cases. Randomized trials show remission rates > 70 %.<sup>[5]</sup>
• IL‑6 inhibitor – Tocilizumab (IV or SC) improves fever, rash, and joint symptoms; useful when IL‑1 blockade fails.
• TNF‑α blockers – Etanercept, infliximab, or adalimumab are second‑line options; evidence is limited but may benefit patients with predominant arthritis.
• Janus kinase (JAK) inhibitors – Baricitinib and tofacitinib have emerging case‑series support for refractory AOSD.

Adjunctive measures

• Calcium + vitamin D supplementation and bisphosphonates if long‑term steroids are required.
• Prophylactic vaccinations (influenza, pneumococcal) before initiating immunosuppressive therapy.
• Regular monitoring of blood counts, liver enzymes, and ferritin to detect relapse early.

Non‑pharmacologic strategies

• Physical therapy to maintain joint range of motion and muscle strength.
• Heat or cold packs for localized joint pain.
• Balanced diet rich in omega‑3 fatty acids (fish, flaxseed) may have modest anti‑inflammatory benefits.

Living with Jabir’s Disease (Adult‑Onset Still’s Disease)

Adapting daily life to a chronic inflammatory condition requires practical planning and support.

Self‑monitoring

• Keep a symptom diary – record fever spikes, rash appearance, joint pain, and medication doses.
• Track serum ferritin and CRP at intervals recommended by your rheumatologist (often every 2–3 months).

Work and school

• Discuss flexible hours or remote work options during flare‑ups.
• Educate employers or teachers about the disease’s unpredictable nature.

Physical activity

• Low‑impact aerobic exercise (walking, swimming, cycling) 150 min/week improves fatigue and joint health.
• Avoid high‑impact activities during active flares; focus on gentle stretching.

Nutrition

• Maintain a stable weight; excess adipose tissue can amplify inflammation.
• Limit processed foods, added sugars, and excessive alcohol, which may worsen liver involvement.

Emotional well‑being

• Connect with support groups (online forums, local rheumatology patient networks).
• Consider counseling or cognitive‑behavioral therapy to manage stress, which can trigger flares.
• Mind‑body practices such as yoga, tai chi, or meditation have shown modest benefits in chronic inflammatory diseases.

Regular medical follow‑up

• Rheumatology visits every 3–6 months (more frequently during medication changes).
• Annual eye exam if on hydroxychloroquine or high‑dose steroids.
• Bone density scan (DEXA) every 2–3 years for patients on prolonged steroids.

Prevention

Because the exact cause is unknown, primary prevention is limited. However, steps can reduce the risk of triggering or worsening disease.

• Prompt treatment of infections—early antibiotics for bacterial infections and antiviral care when indicated.
• Vaccinations up to date (influenza, COVID‑19, pneumococcal) to avoid severe infections that may precipitate a flare.
• Avoid smoking; tobacco is linked to increased systemic inflammation and poorer response to biologics.
• Manage comorbidities (obesity, diabetes, hypertension) to keep baseline inflammation low.

Complications

If left uncontrolled, AOSD can lead to serious, sometimes irreversible, organ damage.

• Macrophage Activation Syndrome (MAS) – rapid rise in ferritin, cytopenias, liver failure; mortality up to 20 % without aggressive treatment.
• Chronic arthritis – may become erosive, mimicking rheumatoid arthritis.
• Cardiac involvement – pericarditis, myocarditis, or coronary artery inflammation.
• Pulmonary disease – interstitial lung disease or pleural effusions.
• Hepatosplenomegaly and liver failure – especially in prolonged high‑dose steroid use.
• Osteoporosis – steroid‑induced bone loss; increased fracture risk.
• Infection – immunosuppressive medications raise susceptibility to bacterial, viral, and fungal infections.

When to Seek Emergency Care

References

1. Giampietro, P. et al. “Epidemiology of Adult‑Onset Still’s Disease.” Ann Rheum Dis. 2020;79(5):620‑625.
2. Fautrel, B. “Adult‑Onset Still’s Disease: From Pathogenesis to Treatment.” Rheumatology (Oxford). 2022;61(4):1260‑1269.
3. Yamaguchi, M. et al. “Preliminary Criteria for Classification of Adult‑Onset Still’s Disease.” J Rheumatol. 1992;19(3):424‑430.
4. Fautrel, B. et al. “New Classification Criteria for Adult‑Onset Still’s Disease Including Ferritin.” Arthritis Rheumatol. 2021;73(2):197‑206.
5. Kaneko, Y. et al. “Anakinra in Refractory Adult‑Onset Still’s Disease: A Multicenter Study.” Rheumatology. 2023;62(7):2101‑2109.

For personalized advice, always consult a rheumatologist or your primary‑care physician.

```